Mr. Ravenscroft has nearly 30 years of experience in the health care industry spanning senior product development and commercial management roles in North America, Europe and Asia. Mr. Ravenscroft joined Lentigen in February 2008. Prior to that, he served as President of Bristol-Myers Squibb's Medical Imaging Business, which he led through a successful sale to Avista Capital Partners LP for $525 million in January 2008. He was also Vice President of Bristol-Myers Squibb's Global Virology Franchise, leading the global launch of Reyataz, a novel HIV drug with annual global sales in excess of $1 billion. Mr. Ravenscroft has held executive and senior positions with DuPont Pharmaceutical's Global HIV Business, where he launched Sustiva, an HIV drug with annual global sales in excess of $1 billion and with Glaxo Wellcome. Mr. Ravenscroft holds a master's degree in Information Science from City University in the United Kingdom and a bachelor's degree in Applied Biology from North East London University.
President and Chief Scientific Officer
Dr. Dropulic has more than 20 years of experience in academia and the biotech industry. Prior to founding Lentigen, he was founder and chief scientific officer of ViRxSys where he successfully led a multidisciplinary team to initiate and complete the first lentiviral vector clinical trial in humans. Previously, Dr Dropulic was an Instructor and then Adjunct Assistant Professor at Johns Hopkins University School of Medicine in Baltimore, Maryland, where he was the first to develop an HIV-based vector targeted to inhibit the replication of the HIV/AIDS virus. Dr. Dropulic was a Fogarty Fellow at the National Institutes of Health where he worked on developing transgenic animals using embryonic stem cell technology, understanding molecular aspects of HIV replication and gene therapy for HIV/AIDS. He is a member of the Infectious Diseases and Industrial Liaisons Committees for the American Society of Gene Therapy and a member of the Editorial Board of the journal Human Gene Therapy. He obtained his Ph.D. from the University of Western Australia focusing upon how viruses cause disease in the body. Dr Dropulic received his B.Sc. (Hons.) from the University of Western Australia and an MBA from The Johns Hopkins University.
Dr. Meade has 30 years experience in the biotech and pharma industry. Before joining Lentigen, in June 2008, he was the Vice President of Business Development for Avalon Pharmaceuticals. Previously he held business development positions at Pharmacia Corporation, Bayer Corporation, Chiron Corporation and Cetus Corporation. Dr. Meade closed numerous deals involving technology or products from early discovery phase up to late stage clinical phase products.
Prior to his business development positions, Dr. Meade held various scientific positions at Cetus Corporation and was a scientific founder of AgraCetus. He has been an active member of the Licensing Executives Society and is a Certified Licensing Professional (CLP). Dr. Meade obtained his Ph.D. and M.S. in Molecular Biology from the University of Texas at Dallas.
